GlassScriptPhysician profile
Darla K Hull
NPI 1952440679
$1,828.36
in general payments reported to CMS, 2019-2025
25 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $199 · 2021: $228 · 2022: $162 · 2023: $342 · 2024: $110 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.87 | 2021-2023 | |
| Pfizer INC. | $230.24 | 2019-2024 | |
| Glaxosmithkline, LLC. | $225.28 | 2019-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $204.56 | 2021-2023 | Freestyle Libre |
| Astellas Pharma US INC | $198.84 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $91.92 | 2022-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $82.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.69 | 2019-2023 | Spiriva Respimat |
| Sunovion Pharmaceuticals INC. | $47.82 | 2019 | |
| Lilly USA, LLC | $46.48 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.23 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $33.08 | 2023-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $30.85 | 2021 | |
| Novo Nordisk INC | $29.37 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.76 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $24.32 | 2019 | |
| Merck Sharp & Dohme LLC | $22.88 | 2025 | Gardasil 9, Capvaxive |
| Idorsia Pharmaceuticals US INC | $20.35 | 2024 | Quviviq |
| Circassia INC. | $18.22 | 2019 | |
| Exact Sciences Corporation | $15.73 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.27 | 2025 | |
| Amgen INC. | $15.21 | 2019 | |
| Boston Scientific Corporation | $14.84 | 2023 | Watchman Access System |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darla Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.